Details for Patent: 10,765,749

« Back to Dashboard

Which drugs does patent 10,765,749 protect, and when does it expire?

Patent 10,765,749 protects ZTLIDO and is included in one NDA.

This patent has fifteen patent family members in eight countries.

Summary for Patent: 10,765,749

Title:	Non-aqueous patch
Abstract:	Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base.
Inventor(s):	Tatsuya Mori, Naoyuki Saida
Assignee:	Oishi Koseido Co Ltd , Itochu Chemical Frontier Corp
Application Number:	US15/891,915
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,765,749
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 10,765,749

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Scilex Pharms	ZTLIDO	lidocaine	PATCH;TOPICAL	207962-001	Feb 28, 2018	AB	RX	Yes	Yes	10,765,749		Y

International Family Members for US Patent 10,765,749

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Brazil	112013028802
Brazil	122021017591
Canada	2835595
European Patent Office	2708229
European Patent Office	3569227